KT-413 (IRAK degrader-1, zomiradomide) is a dual-function PROTAC molecule and a potent degrader of interleukin-1 receptor associated kinase 4 (IRAK4) and the transcription factors Ikaros and Aiolos by acting as both a heterobifunctional degrader and a molecular glue. It can be used in research for developing therapies targeting the activated B-cell (ABC) subtype of diffuse large B-cell lymphoma (DLBCL).